🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

An International Challenge

Gonorrhoea infections are escalating globally, with data suggesting over 82 million new cases annually. Especially elevated rates are reported in the African continent and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, also known as a brand name, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists believe that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in the same week. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization represents a major breakthrough in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Worldwide Availability

According to data detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an equal footing with the current standard treatment, which involves a dual-drug approach. The study enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have expressed optimism. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is viewed as essential to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea globally.